Clinical Trials Browser

Approved for marketing × nilotinib × Clear all

NCT00905593 2012-07-18

ENACT

Approved for marketing

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive